BOSTON - eTradeWire -- Neurobit (https://www.neurobittech.com/), an innovative medtech startup, has been selected as the first-ever Taiwanese company to be on the Global Eddies 2025 cohort, marking a significant step to expand into the U.S. market. The company will showcase its AI-powered diagnostic medical device during the Global Eddies Demo Day on March 26, 2025, a virtual event that will introduce Neurobit to key stakeholders in the U.S. healthcare and investment ecosystems.

This milestone highlights Neurobit's dedication to overcoming the current challenge in dizziness and vertigo diagnosis through objective and precise assessments. Vertigo, dizziness and balance-related conditions are among the most common health problems in adults. Nearly 40 percent of U.S. adults experience vertigo at least once in their lifetime. These conditions can arise from issues with the vestibular system, which includes structures of the inner ear, vestibular nerve, brain stem and cerebellum, a region of the brain that integrates sensory perception, coordination and motor control (source: UCSF Health). Current diagnostic methods heavily rely on manual exams, patient-reported symptoms, and physician experience.

More on eTradeWire News

• Bestselling Author and Poet Uplifts Readers with Reflections on Faith, Resilience & Social Justice
• Valency International Partners with Cognitud to Advance ESG and Climate Transformation Agenda
• Thankz Global Staffing Announces Rebrand to Thankz Talent Solutions
• Introducing Continuity OS™ for Authority Execution During Incapacity and Transition
• Travel job seekers jump 62% in Jan

"Traditional vestibular function tests take up to an hour to complete", said Travis Yang, Co-Founder & CEO of Neurobit. "Our products reduce test time to just 5 to 10 minutes, improving both efficiency and accuracy." Neurobit's technology enhances patient care by reducing diagnostic errors while offering healthcare providers a more cost-effective solution for patient management.

In January 2025, Neurobit was selected to join Global Eddies, an integrator program designed to help international startups and SMEs establish a presence in the Northeast U.S. innovation ecosystem. "We only accept a handful of startups in the program each year; selection factors include the degree of innovation and benefits offered to the target group", said Sophia Kambanis, Executive Director of Massachusetts Innovation Network, the organizer of Global Eddies. "With the support of the program, we refine our go-to-market strategy, and build connections with potential partners, investors and customers.", said Travis Yang.

More on eTradeWire News

• Municipal Carbon Field Guide Launched by LandConnect -- New Revenue Streams for Cities Managing Vacant Land
• A's On The Way Roadside Expands 24/7 Emergency Assistance Across Overland Park & KC
• Hoy Law Wins Supreme Court Decision Establishing Federal Trucking Regulations as the Standard of Care in South Dakota
• Sunday Salsa & Bachata lesson + Valentines Latin Night Feb 15, 2026
• 1Essay.org Launches February 2026 Welcome Initiative with 10% Discount for New Clients

Neurobit has established a network of distributors and customers across Asia and Europe, and is now actively penetrating the U.S. market. Several U.S. distributors have scheduled online product demonstrations with the Neurobit team, and the company expects to receive more interest throughout the year.

About Neurobit
Founded in 2016 in Taiwan, Neurobit is a trailblazing medtech company specializing in AI-powered diagnostic devices for dizziness and vertigo. By using advanced eye-tracking technology, Neurobit offers healthcare providers a faster, more accurate way to diagnose and treat patients, improving clinical outcomes and operational efficiency. The company is actively expanding into the U.S. market, aiming to transform healthcare diagnostics and solidify a strong presence in the rapidly growing medtech industry.